Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.70 |
| ▸ | CDC7 | O00311 | 4/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.63 |
| ▸ | PRKACA | P17612 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.63 |
| ▸ | CDK2 | P24941 | 3/20 | 0.63 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.63 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.63 |
| ▸ | PIM1 | P11309 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | AXL | P30530 | 3/20 | 0.61 |
| ▸ | CDK8 | P49336 | 2/20 | 0.61 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.56 |
| ▸ | CLK2 | P49760 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740263 | 0.96 | CAMKK2 (0.69) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL18418494 | 0.89 | CDC7 (0.71) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL20846288 | 0.88 | CAMKK2 (0.60) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL859052 | 0.86 | CAMKK2 (0.62) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL858766 | 0.85 | CAMKK2 (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL5907880 | 0.85 | CAMKK2 (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL10395104 | 0.85 | CDC7 (0.70) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL31064980 | 0.85 | CDC7 (0.70) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL857678 | 0.84 | IKBKE (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL20292820 | 0.83 | DYRK1B (0.71) | CAMKK2CDC7MAP4K4CLK4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CAMKK2 103/4885CDC7 129/4885MAP4K4 23/4885 |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CAMKK2 100/4885CDC7 161/4885MAP4K4 37/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CAMKK2 100/4885CDC7 161/4885MAP4K4 37/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CAMKK2 100/4885CDC7 161/4885MAP4K4 37/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CAMKK2 100/4885CDC7 161/4885MAP4K4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.